Eaton Vance Management Sarepta Therapeutics, Inc. Transaction History
Eaton Vance Management
- $67.5 Billion
- Q3 2022
A detailed history of Eaton Vance Management transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, Eaton Vance Management holds 27,375 shares of SRPT stock, worth $3.12 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
27,375
Previous 22,397
22.23%
Holding current value
$3.12 Million
Previous $1.68 Million
80.23%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding SRPT
# of Institutions
526Shares Held
84.5MCall Options Held
2.06MPut Options Held
1.52M-
Black Rock Inc. New York, NY10.3MShares$1.18 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.97MShares$1.02 Billion0.02% of portfolio
-
Capital International Investors Los Angeles, CA6.26MShares$714 Million0.16% of portfolio
-
Janus Henderson Group PLC London, X04.36MShares$497 Million0.29% of portfolio
-
State Street Corp Boston, MA4.27MShares$487 Million0.02% of portfolio
About Sarepta Therapeutics, Inc.
- Ticker SRPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 87,567,904
- Market Cap $9.99B
- Description
- Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...